News
-
-
PRESS RELEASE
DEFENCE’S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM PLATFORM FOR CANCER TREATMENTS ON MONEY TALK RADIO WITH ELLIS MARTIN
Defence Therapeutics Inc.'s Chief Scientific Officer Dr. Moutih Rafei discusses the ACCUM platform for cancer treatments on Money Talk Radio with Ellis Martin -
-
PRESS RELEASE
DEFENCE TO PARTICIPATE TO 2024 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ANNUAL MEETING IN TORONTO ON JUNE 11, 2024
Defence Therapeutics Inc. to participate in the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024, presenting their novel Radio-Immuno-Conjugate (RIC) for cancer treatment -
-
PRESS RELEASE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
Defence Therapeutics Inc.'s AccuTOX published in the prestigious Journal of Translational Medicine along with preclinical data on AccuTOX as an anti-cancer molecule. Study highlights AccuTOX's superior therapeutic properties and versatility for different cancer treatments -
-
PRESS RELEASE
DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
Defence Therapeutics strengthens and expands global patent protection on key technologies, including vaccine enhancer platform and ADC platform technology. The new patents and allowances showcase the company's commitment to innovation in biopharmaceuticals -
-
PRESS RELEASE
PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE
Defence Therapeutics Inc. successfully completes pre-clinical trial using its ARM-002 anti-cancer vaccine against pancreatic cancer, showing therapeutic effectiveness and potential benefits
![Accesswire](/assets/images/accesswire-inline.png)
-
APWG 2024 Cybercrime Research Conference Extends Submission Deadline to July 7
-
Product Creation Studio Partners With PatchClamp Medtech Inc. to Develop Revolutionary Dural Repair System
-
XS Financial Enters Into Definitive Agreement to Be Taken Private
-
TRU Engages Investor Relations Specialists HE Capital Markets
-
DuJour Media Jason Binn Celebrates Successful 12th Anniversary Cover Party with Star-Studded After-Party and Record Turnout
![EQS Group](/assets/images/eqs-group.png)
-
HORNBACH Group delivers strong Q1 2024/25 results increasing earnings per share y-o-y by 44% – full-year outlook confirmed unchanged
-
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
-
Meyer Burger makes significant progress in relocating its core business to the USA
-
BIRKENSTOCK ANNOUNCES LAUNCH OF SECONDARY OFFERING
-
CureVac Announces Voting Results of General Meeting
![Les Echos](/assets/images/les-echos.png)
-
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2024
-
2023/2024 Third Quarter Sales
-
Disclosure of trading in own shares from June 17th, 2024, to June 21th, 2024. Detailed information per transaction
-
Disclosure of trading in own shares from June 17th, 2024, to June 21th, 2024
-
imerys-24-06-2024-information-share-capital-and-voting-rights-as-of-31-may-2024